Respira Therapeutics, Inc.

Hugh Smyth

Martin J Donovan

Robert Curtis

Zhen Xu

Revati Shreeniwas

Dan Deaton

James Hannon

Aileen Gibbons

Jeffry G Weers

Alain Romero

Adaani Frost

Pravin L Soni

Stephen Lermer

Jacques Pappo

Robert M Curtis

Novel dry powder compositions comprising and methods relating thereto are provided. The dry powder compositions comprise PDE5 inhibitors, such as vardenafil, or pharmaceutically acceptable salts or esters thereof. The dry powder compositions may optionally include an carrier/excipient. The concentration of active agent may be at least about 2% by weight. Methods of aerosolizing the dry powder compositions and using them to treat various diseases are also disclosed.

PDE5 inhibitor powder formulations and methods relating thereto

Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE5 inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.

Methods and compositions for treatment of pulmonary hypertension and other lung disorders

A dry powder inhaler includes a powder storage element configured to hold a powdered medicament and an inlet channel receives powdered medicament from the powder storage element that is entrained in an airflow. The inlet channel has a first diameter and defines an opening. The inhaler includes a dispersion chamber that receives the airflow and the powdered medicament from the opening. The dispersion chamber has a second diameter. The inhaler includes an actuator housed within the dispersion chamber. The actuator oscillates within the dispersion chamber when exposed to the airflow to deaggregate the powdered medicament entrained by the airflow passing through the dispersion chamber. A ratio between the first diameter and the second diameter is between about 0.40 and 0.60 such that an audible sound is produced as the actuator oscillates. The inhaler includes an outlet channel through which the airflow and powdered medicament exit the inhaler.

Powder dispersion methods and devices

Methods for treatment of pulmonary hypertension

Powder inhaler, system and methods

A dry powder inhaler may include a powder storage region, an inlet channel, a dispersion chamber, and an outlet channel. A geometry of the inhaler may be such that a flow profile is generated within the dispersion chamber that causes an actuator to oscillate, enabling the actuator when oscillating to deaggregate powdered medicament within the dispersion chamber to be aerosolized and entrained by the air and delivered to a patient through the outlet channel.

Inhaler to deliver substances for prophylaxis or prevention of disease or injury caused by the inhalation of biological or chemical agents

A dry powder inhaler includes a chamber holding a bead-like actuator to which a powdered medicament is adhered. Air is drawn into the chamber through an inlet flow channel and exits through an outlet flow channel. The bead-like actuator oscillates in response to the air flow, dislodging powdered medicament to be entrained in the air flow and delivered to the patient.

Bead-containing dry powder inhaler

A dry powder inhaler includes a chamber holding an actuator to which a powdered medicament is adhered. Air is drawn into the chamber through an inlet flow channel and exits through an outlet flow channel. The actuator oscillates in response to the air flow, dislodging powdered medicament to be entrained in the air flow and delivered to the patient. A retaining member prevents the actuator from exiting the chamber. Thus, the medicament may be delivered to the patient without the use of carrier particles.

Dry powder inhaler

Growing community of inventors

West Lake Hills, TX, United States of America

Hugh Smyth